Nautilus Biotechnology (NASDAQ:NAUT) CEO Sujal M. Patel Buys 83,500 Shares

Key Points

• Nautilus Biotechnology CEO Sujal Patel purchased 83,500 shares at an average price of $0.68, increasing his ownership stake to over 10 million shares valued at approximately $7 million.
• The company's stock saw a decline of 4.4% on Tuesday, trading at $0.67, with a market cap of $84.63 million.
• Analysts expect Nautilus Biotechnology to report -0.57 EPS for the current fiscal year, despite having topped previous earnings estimates.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel bought 83,500 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were acquired at an average price of $0.68 per share, with a total value of $56,780.00. Following the purchase, the chief executive officer owned 10,341,721 shares in the company, valued at $7,032,370.28. This trade represents a 0.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Nautilus Biotechnology Trading Up 2.1%

NASDAQ:NAUT traded up $0.01 during mid-day trading on Friday, hitting $0.72. 280,945 shares of the company's stock traded hands, compared to its average volume of 238,015. The firm has a 50 day moving average of $0.73 and a two-hundred day moving average of $0.79. Nautilus Biotechnology, Inc. has a 12 month low of $0.62 and a 12 month high of $3.09. The firm has a market capitalization of $91.03 million, a price-to-earnings ratio of -1.39 and a beta of 1.42.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. As a group, equities research analysts expect that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $34,000. Squarepoint Ops LLC bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $44,000. Presidio Capital Management LLC lifted its position in shares of Nautilus Biotechnology by 246.6% in the 2nd quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after acquiring an additional 24,664 shares during the period. XTX Topco Ltd bought a new stake in shares of Nautilus Biotechnology in the 1st quarter worth approximately $31,000. Finally, Millennium Management LLC bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth approximately $63,000. Institutional investors own 50.71% of the company's stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.